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Abstract
Objective: As we enter the third decade of the opioid crisis, opioid misuse continues its devastating toll on young women,
specifically mothers on Medicaid in rural areas. The evolving Medicaid policy landscape has led to coverage and benefit
expansion; yet gaps remain for pregnant women with opioid misuse. Further, the myriad of state specific policy decisions
related to maternal eligibility and substance abuse benefits have created a seemingly disjoint policy arena for tackling a specific
subgroup’s unmet needs. This policy scan aims to investigate the newly implemented 1115 demonstration model for Maternal
Opioid Misuse by comparing the approaches of four rural states.
Methodology: All documentation for each demonstration model and waiver were reviewed and analyzed for rural specific
content. Policy language referencing rurality or rural concepts were then identified, categorized, and codified for comparison
across the four sample states. Finally, policy and programmatic approaches which were inherently rural were identified and
compared between the four states. This analysis concludes with a brief synthesis of the results, as well as a discussion on what
gaps may remain.
Results: Of the two states submitting 1115 Waivers, both (IN, MO) expand eligibility to Medicaid for mothers with opioiduse disorder, but only MO expands Medicaid benefits. Of the three states (CO, IN, ME) implementing the demonstration
model, two (CO, IN) leverage health insurance payers as partners while ME partners with local health system providers. Three
states (CO, MO, ME) add telehealth and peer support services as authorized Medicaid benefits for mothers with an opioid-use
disorder. Only ME used the innovation model to authorize Medicaid to reimburse, provider-to-provider telehealth capacity
building models.
Conclusion: This study highlights and reaffirms the variation in Medicaid policy at the state level. Expanding Medicaid
benefits to reimburse necessary telehealth and peer support services may help address service availability gaps in rural regions.
Future research should leverage the continual expansion of these MOM models, especially evaluating differences between rural
and non-rural outcomes. The excessive morbidity facing these young mothers warrants prompt evaluation and dissemination
to promote diffusion across the country until this public health crisis is fully extinguished.
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BACKGROUND

who is affected. Although it was assumed that middleaged men represented a disproportionate share of those
experiencing opioid-related deaths and hospitalizations,
women have not been immune to the effects of the crisis (Hollander et al. 2019). But contrary to the experience of men, where the risk of opioid-use disorder (OUD)
peaks at middle age, the risk in women peaks during reproductive age (Jumah 2016; Ahrens et al. 2021).

As we enter the third decade of the opioid crisis, opioid
misuse continues its devastating toll. Between September 2019 and September 2020, the Centers for Disease
Control (CDC) estimated that 81,000 adults died from
opioid misuse (Ahmad 2021). Yet, as the public health
emergency persists, so too does our understanding of
1

2

Over the past decade, OUD during pregnancy has
risen 400% (Hollander et al. 2019). OUD among pregnant women significantly elevates the risk of maternal
mortality, both before discharge and within a year of
delivery (Roper and Cox 2017; Weller et al. 2021). Estimated to be 5% nationally, the distribution of opioid
misuse during pregnancy varies considerably by geography (Jumah 2016). The prevalence of opioid misuse
among pregnant women appears to be highest in states
with larger rural populations and has exceeded 10% in
certain rural groups, specifically rural Medicaid beneficiaries (Ahrens et al. 2021).
To better respond to the public health crisis of mothers
misusing opioids, two policies were enacted to promote
targeted innovation within Medicaid programs. The
first policy approach stems from 1115 waivers designed
to directly target innovation towards treating pregnant
women using opioids (KFF 2021). Two states have submitted maternal opioid misuse waivers: Indian and Missouri. Missouri’s waiver was adopted April 16, 2021 and
will take effect January 1, 2022 (MO 2021). Indiana’s
maternal opioid misuse waiver was submitted October
20, 2020 but withdrawn June 6, 2021 (MOMII 2021).
The other approach to adapt Medicaid programs to better treat maternal opioid misuse came from a CMS call
for demonstrations. These demonstrations funded state
Medicaid programs developing health system partnerships and designing integrated care systems throughout
the pre and post-partum continuum for women using or
at risk of misusing opioids (CMS 2019). As of April 30,
2021, nine states have begun implementing the Maternal Opioid Misuse (MOM) model (CMS 2019). By integrating appropriate maternal care and opioid use treatment and expanding the scope and eligibility of Medi-
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caid coverage, these innovative Medicaid demonstration
models have the potential to lower hospital costs, improve pregnancy outcomes, and reduce maternal mortality. Yet, despite the disproportionate burden of opioid
misuse among mothers in rural regions, the extent to
which these models directly focus on improving health
outcomes in rural settings remains unknown.

OBJECTIVE
To fill this knowledge gap and inform predictions for
the efficacy of these models for reducing hospital costs
and maternal mortality, this study aims to conduct a
policy scan of states implementing MOM waivers and
models. In addition to comparing the approaches of
these state models, this analysis will specifically identify approaches within each 1115 waiver or demonstration authority which may impact rural mothers and rural
providers. Understanding how states adapt their Medicaid program to reduce rural maternal opioid misuse will
inform best-practice policy implementation as the MOM
model diffuses across the country and we enter the third
decade of the American opioid crisis.

LITERATURE REVIEW
Before comparing these novel Medicaid policies addressing maternal opioid misuse in rural Medicaid populations, this paper begins by briefly reviewing the history
of Medicaid policies impacting maternal health and substance use in America.

Treating a Public Health Crisis for Rural Moms
Maternal Mortality
Maternal mortality includes all pregnancy-related deaths
within one year of giving birth. In part due to the opioid
crisis, as well as other socioeconomic and structural factors, maternal mortality in the United States is the highest among wealthy countries (Roosa 2020). For decades,
federal and state agencies in the United States have
launched policy initiatives intended to reduce maternal
mortality. Outside the healthcare sector, policies such
as supplemental nutrition assistance programs, temporary assistance for needy families, and the earned income
tax credit were all designed to help lower-income families, especially mothers living in poverty. But within the
healthcare system, the major policy reform was Medicaid
which, in 1984, began requiring all states to add a categorical designation to cover low-income pregnant women
(P.L. 98369 1984). Over the years, Medicaid coverage for
pregnant women continued to expand (MACPAC 2021).
Today, more than 40% of all U.S. births are financed by
Medicaid (CDC 2018).
While these policy reforms increased prenatal care visits and improved delivery outcomes, maternal mortality
remained higher in America than peer nations (Roosa
2020). Recently, evidence began to suggest that the difference in maternal mortality between U.S. and other
wealthy countries was highest more than one month after delivery (Roosa 2020). Apparently, mothers in the
U.S. were at no greater risk of dying during delivery
or within thirty days of discharge. However, due to
longer term complications and untreated physical and
emotional health, U.S. mothers were more likely to die
between 31-360 days after delivery.
The recent evidence illuminated a weakness in Medicaid policy. Most low-income women lose their Medicaid coverage 30 days after giving birth, when their risk
of maternal mortality is highest. For many elected officials, addressing this gap became a major policy priority.
In 2020 alone, ten bills were introduced into the federal Legislature which expanded Medicaid post-partum
coverage (KFF 2021). Eventually, the American Rescue
Plan (ARP) included the statutory language of these
bills’ and offered states an option to extend full Medicaid coverage to pregnant women up to one year after
delivery (H.R. 1319 2020). While this statute only allows states to grant such extensions through 2026, this
Medicaid reform is likely to remain as removing Medicaid benefits from a vulnerable group has not proven
to be politically popular, even in states with the least
generous Medicaid coverage.
Behavioral Health and Substance Use
Just as with pregnancies, Medicaid is the largest payer
for behavioral health and substance use treatment in the
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U.S. (MACPAC 2015). More than one in three nondually eligible adults on Medicaid reported a mental illness or substance use disorder (MACPAC 2015). However, throughout most of Medicaid’s legislative history,
the program has been plagued by gaps in coverage, lack
of parity, and discoordination (i.e. “same day billing
glitch”) (P.L. 114-255 2016).
One gap related to where behavioral health and substance use treatment could be provided. To avoid financing costly state-managed psychiatric hospitals, Medicaid
explicitly excluded benefits which covered treatment at
“Institutes of Mental Disease” (Maclean et al. 2021).
Although, despite the statutory exclusion, states continue to reimburse Medicaid funds to such institutions
(GAO 2019). Still the exclusion restriction appears to
be impeding appropriate care. Mental health advocates consider the exclusion restriction discriminatory,
as well as a potential barrier towards achieving behavioral health integration (MACPAC 2016). As a response,
recent legislative efforts have begun to relax the exclusion restriction, starting with new demonstration authority under the Affordable Care Act (P.L. 111-148 2010).
Most relevant to the opioid crisis, however, was the SUPPORT Act of 2018, a law which authorized Medicaid to
cover behavioral health services for pregnant women who
were concurrently receiving opioid-related substance use
treatment at an Institute of Mental Disease (P.L. 114271 2018).
An additional motivation to exclude Institutes of Mental Disease, defined as a large inpatient behavioral health
facility with more than sixteen beds, stemmed from Medicaid’s objective for providing care in community-based
settings. This objective became more achievable in 1981,
after Congress passed the Omnibus Budget Reconciliation Act (OBRA), instituting 1915(c) waivers (P.L. 9735 1981). These newly authorized 1915(c) waivers allowed states to expand Medicaid services to adults with
specific clinical diagnoses to avoid institutionalized care.
However, while 1915(c) waivers offered greater potential
access to services, states varied widely in what clinical
categories were covered, how many waivers to grant, and
the types of services would be provided. In 2018, only
eleven states adopted 1915(c) waivers for mental health,
with enrollment ranging from 100 to 6,400 (KFF 2018).
More recently, Medicaid’s 1115 Behavioral Health
Demonstration Waivers have gained popularity as an approach to fill gaps in Medicaid behavioral services (KFF
2017). As of 2017, 22 states have adapted their Medicaid
program by waiving regulations related to financing, service delivery, and eligibility for behavioral health or substance use Medicaid benefits. In addition to waiving the
Institutes of Mental Disease exclusion restriction, states
have also used these 1115 Behavioral Health Waivers
to expand Medicaid eligibility to cover specific, at-risk
groups. Other states have extended the scope of their
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community-based behavioral health services above the
statutory authority derived from 1915(c) waivers. Examples include Medicaid benefits to provide housing or
employment support and peer recovery coaching. Seven
states have specifically targeted their 1115 Behavioral
Health Waivers towards adapting substance use treatment models within their Medicaid program. Inherently
designed as demonstrations with a critical evaluation
component, the findings from these seven states will illuminate future pathways for integrating substance use
treatment across the care continuum, as well as identify if
potentially burdensome regulations related to inpatient
day limits impact outcomes. As a signal of continued
support for innovation, 2017 CMS Guidance required
that states adopting 1115 Behavioral Health Waivers begin incorporating demonstration components related to
opioid prescribing, opioid antagonists, and opioid misuse
care coordination (CMS 2017).
Maternal Opioid Misuse Models
The evolving Medicaid policy landscape has led to
coverage and benefit expansion for low-income adults.
Yet, gaps remain for pregnant women with opioid misuse. Medicaid eligibility thresholds vary widely between
states expanding and non-expanding Medicaid, especially for women of reproductive age. Further, the myriad of state specific policy decisions related to maternal eligibility and substance abuse benefits have created
a seemingly disjointed policy arena for addressing unmet needs of a vulnerable group. Finally, despite the
growth in behavioral health services and added flexibility for state designed Medicaid models, pregnant women
with potential opioid use disorder have not, until recently, been the focus of Medicaid innovation. Instead,
care for pregnant women and new mothers using opioids remained fragmented. The outcomes were especially
dire in rural contexts, where comprehensive services may
be less available due to maternal care and substance
use treatment provider shortages (Patrick et al. 2015;
ACOG 2017). Whether the newly authorized Medicaid
MOM waivers and demonstration models addressed their
barriers to care remain unknown.
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mentation relevant to the MOM Demonstration. States
without publicly available and readily accessible documentation were excluded from the analysis. In addition to obtaining documentation for states implementing
CMMI models, the CMS waiver list was scanned to identify which states submitted a MOM 1115 waiver (CMS
2021). All files within a 1115 Waiver submission were
then obtained for review.
All documentation was retrieved and analyzed between January 1, 2021 and April 30, 2021. First,
the scope and policy approaches of each demonstration were reviewed and categorized. Categories included
health system partnerships, coverage or benefit expansion, and Medicaid innovation. The documentation for
each demonstration model and waiver was then analyzed
for rural specific content by identifying policy language
explicitly describing rural populations, providers, and
contexts, or policy language implicitly related to concepts for accessing high-quality care in rural provider
shortage areas. All policies and approaches were then
compared across states. This analysis concludes with a
brief synthesis of the results, as well as a discussion on
what gaps may remain, for which future MOM models
could incorporate to better address the needs of rural
moms misusing opioids.
RESULTS: POLICY SCAN
This policy scan identified nine states which either implemented a CMMI MOM Demonstration Model or submitted a 1115 MOM Waiver. Of these nine states, eight have
rural populations (CO, IN, ME, MO, NH, TN, TX, WV).
Maryland, which has no rural designated county, was
excluded from this analysis (USDA 2021). Two states
(MO, IN) submitted 1115 Medicaid Waivers to adopt
Medicaid service delivery (CMS 2021). Among the remaining seven states implementing a MOM model with
rural populations, only two states (CO, ME) had publicly available and readily accessible MOM model documentation (i.e. plans, presentations, committee meeting
notes, fact sheets) on their state Medicaid website (CO
Medicaid 2021, ME Medicaid 2021). See figure 1 for the
inclusion criteria flow chart. See table 1 for a breakdown
of state inclusion criteria and sources.

POLICY SCAN METHODOLOGY
To determine how states adapted their Medicaid program to specifically address rural maternal opioid misuse, this study first identified which states were participating in the newly authorized Center for Medicare
and Medicaid Innovation (CMMI) MOM Demonstration. Given the focus on rural mothers, this study used
Rural-Urban Continuum Codes to exclude states which
did not have any rural designated counties (USDA 2021).
Next, each state’s Medicaid site was searched for docu-

RESULTS: DEMONSTRATION
APPROACHES (TABLE 2)
Colorado
The Colorado state Medicaid program was among the
eight grantees of the CMMI award (CMS 2021). This
state had not submitted a waiver and provided no documentation to indicate such a 1115 waiver for Maternal
Opioid Misuse may be forthcoming. The key features
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of the Colorado demonstration model relate to the community partners, services available to beneficiaries, and
model for delivering services (CO 2021).
The Colorado model identified five community partners under the CMMI MOM model. All five of these
partners are health insurance plans, which cover Medicaid beneficiaries across the entire state. Colorado has
designed its Medicaid program so an insurance payer facilitates care delivery at a regional level. These five insurance payers cover seven mutually exclusive Colorado
regions. All of the community partners include at least
one rural county.
Along with focusing on integrating maternal and postpartum care with substance use and behavioral health
services for mothers using opioids, the Colorado MOM
model expands Medicaid benefits for eligible mothers.
Most noteworthy for rural care, Colorado explicitly expands the authorized use of telehealth for a bundle of
therapy and rehabilitation services. Further, due to the
shortage of qualified providers in rural counties, each
of the partners has expanded the scope of peer support
services. Finally, while no documentation or evaluation
plans were made explicit, the Colorado model defines
“expanding rural provider capacity” as a primary goal
of the CMMI initiative.
As of April 30, 2021, the Colorado model has yet
to design and implement an integrated care program.
However, the unique feature of partnering with regional
health insurance payers yields a statewide approach to
leverage partnerships with smaller providers. To deliver
the integrated opioid misuse treatment across the prenatal and postpartum continuum, each Colorado region
will be providing subgrantees funds to administer services. Given the large geographic swaths of rural regions
in Colorado with fewer and smaller providers, granting
funds to the largest providers could have disproportionately excluded clinics with lower capacity. This motivated the regional approach, which allows each health
insurance payer to utilize multiple partnerships with
smaller clinics and providers to deliver care across the
state.
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provide integrated services for pregnant women misusing opioids, Indiana also aimed to expand their Medicaid program by submitting a new 1115 Waiver (MOMII
2021). This waiver expands the eligibility criteria for
Medicaid benefits, which includes standard Medicaid
prenatal, postpartum, behavioral health, and opioid use
benefits. Rather than expand benefits, the waiver expands eligibility and length of coverage for pregnant
women and new mothers. Prior to the new waiver, pregnant women up to 213% FPL qualify for Medicaid benefits for 60-days post-partum. With the new waiver,
women who 1) maintain continuous income eligibility,
2) sign a CMMI cooperative agreement, and 3) have a
diagnosed opioid-use disorder can maintain their Medicaid benefits for up to one-year postpartum.
The 1115 waiver submitted by Indiana did not aim
to expand Medicaid benefits or address provider shortage areas in rural contexts. On June 20, 2021, Indiana
withdrew their MOM 1115 Waiver application because
of the state expanding Medicaid coverage to all pregnant women after implementation of the American Rescue Plan (Indiana 2021).
Missouri
Contrary to Indiana’s 1115 Waiver, not only does Missouri expand the eligibility of their Medicaid program,
but Missouri also expands the set of benefits for the
newly eligible population (MO 2021). Under the new
Missouri waiver, women with a diagnosed opioid-use disorder with incomes under 196% of FPL can qualify for
Medicaid benefits for twelve months postpartum. The
waiver also extends a range of new behavioral health and
opioid use treatment benefits to this population, covering extensive and comprehensive options for therapy and
rehabilitation services. Most noteworthy for rural populations, however, is the expanded scope of practice for
peer support specialists. This scope of practice authority was only authorized for postpartum mothers with an
opioid-use diagnosis.
Maine

Indiana
Indiana, like Colorado, also identified four private health
insurance payers as the community partners in their
MOM model. However, Indiana’s Medicaid system isn’t
divided into geographic regions, but rather each of the insurance payers cover non-mutually exclusive segments of
the Medicaid market. While this approach may increase
competition, the lack of public documentation limits the
public’s ability to determine if this MOM model provides assurances that integrated care providers will be
available for the entire state.
In addition to participating in the CMMI program to

The final state in this analysis implemented their MOM
model through the CMMI initiative. While staying true
to the goals of the MOM model, Maine took considerably different approaches than the other states. Maine
differentiates themselves from Colorado and Indiana by
partnering with healthcare system providers instead of
health insurance payers (CMS 2019). Additionally, not
only did Maine offer the greatest transparency in the design and implementation process (by publishing committee meetings, program implementation files, and Medicaid reports), but may also be implementing the most
robust MOM program for rural states (ME 2021). Un-
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like the other states, all MOM model services are reimbursed on a capitated, per member per month rate. Finally, documentation from the most recent MOM Model
committee meeting indicate that Maine will be submitting a State Plan Amendment (SPA) to their Medicaid
program to further expand the scope and breadth of the
MOM model.
Maine partnered with five large health systems, which
include providers across the state and cover integrated
care services in or near rural areas. By partnering with
providers, Maine aimed to ensure adequate availability of covered services but also designed programs to
navigate beneficiaries to appropriate services at different providers. To accomplish this goal, Maine is adopting a “No Wrong Door” approach, where at all entry
points of the care continuum (prenatal, delivery, postpartum) women are screened and identified for opioid
misuse, then navigated (with a peer support specialist)
towards appropriate substance use and behavioral health
treatment.
In addition to this “No Wrong Door” approach to delivering integrated care, Maine has also begun to implement two additional programs. The first is a public
outreach and education campaign designed to increase
awareness of the MOM model, but more importantly address issues related to stigma surrounding maternal opioid misuse. No other states explicitly detailed any such
education program in their CMMI initiative. Maine also
includes a workforce component, which includes navigating eligible beneficiaries to employment opportunities
but also navigating healthcare workers who may have
lost their jobs due to COVID-19 to new employment in
the MOM model.
From a rural standpoint, the most promising component of the Maine MOM model is the integration of
MaineECHO (Expanding Collaborative Healthcare Opportunities). MaineECHO builds off the ECHO model
to utilize telehealth to bring together providers in rural areas with specialists at larger, academic hospitals.
MainECHO’s goal is to expand rural provider capacity,
and is now being integrated into maternal opioid misuse
for the first time. This provider-to-provider telehealth
training model has been shown to be successful across
a range of treatments and specialties, and despite being
underutilized, has been especially effective as a Medicaid
program (Semprini 2020). By adding ECHO to Maine’s
MOM model, rural beneficiaries gain access to specialized services without undergoing the burden of travel
or out-of-network barriers. Additionally, rural providers
gain necessary capacity to continue providing necessary
and appropriate services without loss of revenue or loss
of connection with their rural patients.
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CONCLUSION
This policy scan identified approaches where states
adapted their Medicaid programs to address the maternal opioid misuse public health crisis. While both the
states submitting 1115 Waivers expanded Medicaid eligibility to postpartum mothers, the income range differed
between IN and MO. It remains unknown whether the
differences in eligibility were due to contextual factors influencing maternal poverty in each state, or if ideological
and political factors are driving these eligibility criteria.
Further, only Missouri expanded the set of Medicaid benefits for the newly eligible postpartum beneficiaries with
OUD. As the demonstration waivers proceed and eventually conclude, such benefit variation could inform future
policymaking by identifying the most important and effective benefits for treating maternal opioid misuse. Regarding rural issues, however, neither of the 1115 waivers
specifically addressed rural barriers or the need to adapt
Medicaid policy to accommodate rural contexts. Given
the shortage of providers in rural areas, states could not
only expand the use of telehealth and peer support specialists, but relax network adequacy constraints, ban disenrollment for rural beneficiaries, and incentivize rural
Medicaid provider participation. Finally, while Indiana
withdrew their MOM 1115 waiver to expand Medicaid
coverage after the passage of the American Rescue Plan,
the state may need to revisit after the American Rescue
Plan authority ends in 2026.
Most of the variation in state decisions came from
within the CMMI MOM models. While Colorado and Indiana utilized health insurance payers as partners, Maine
included health system providers. Again, only at the
conclusion of the demonstration will we be able to evaluate which approach may be most effective. Future research should also investigate whether the decision to include payer or providers was driven by the needs of the
beneficiaries, or if state market factors or political ideology were driving such decisions. However, that none
of the states made evaluation plans publicly available
may hinder the public’s ability to evaluate demonstration models. CMMI and state Medicaid programs should
all strive for greater transparency going forward.
And while Missouri, Colorado, and Maine included
telehealth and peer support specialist benefits to accommodate rural beneficiaries, only Maine adopted a
highly modern model of telehealth: the ECHO model
of provider-to-provider capacity building. This ECHO
model continues to show its flexibility for different contexts, states, diseases, and populations. With the potential to revolutionize rural care delivery while minimizing specialty-care costs and patient burden, by including
provider-to-provider telehealth models in demonstration
projects we can continue to monitor and evaluate the
efficacy of such novelty. Future research should lever-

Treating a Public Health Crisis for Rural Moms
age the continual expansion of these models, especially
for this specific population. If rural mothers with opioid use disorder struggle to access available services in
rural areas, the Maine ECHO MOM model provides a
clear scenario for which to rigorously investigate. The
excessive morbidity facing these young mothers warrants
prompt evaluation and dissemination to promote diffusion across the country until this public health crisis is
fully extinguished.
Jason Semprini is an NIH
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Public Health. Prior to beginning his PhD in Health
Services & Policy, he earned
his Master’s in Public Policy
at the University of Chicago
as a Susan G. Komen Cancer
Disparities Scholar. His research on Medicaid and Rural Health has been published in peer reviewed journals and presented at national conferences. A lifelong Iowan,
Jason lives in Iowa City with his wife and two daughters.

REFERENCES
ACOG. (2017). Opioid Use and Opioid Use Disorder in
Pregnancy. ACOG Committee Opinion, 711, 14.
Ahmad FB, Rossen LM, Sutton P. (2021) Provisional
drug overdose death counts. National Center for
Health Statistics.
Ahrens, K. A., McBride, C. A., O’Connor, A., & Meyer,
M. C. (2021). Medication for Addiction Treatment
and Postpartum Health Care Utilization Among Pregnant Persons With Opioid Use Disorder. Journal of
Addiction Medicine, Publish Ahead of Print. https:
//doi.org/10.1097/ADM.0000000000000827
CDC. (2018). Births: Final Data for 2016. National
Vital Statistics Reports, Volume 67(1), 55.
CMS (2017).
Strategies to Address the Opioid Epidemic.
Federal Policy Guidance.
https://www.medicaid.gov/federal-policyguidance/downloads/smd17003.pdf
CMS (2019). Maternal Opioid Misuse Models (MOM)
CMS Innovation. https://innovation.cms.gov/
innovation-models/maternal-opioid-misusemodel
CMS (2021). Medicaid Waiver List.
Colorado Medicaid (2021). Maternal Opioid Misuse
Model.
https://hcpf.colorado.gov/maternalopioid-misuse-model
GAO. (2019).
Report to Congress on Oversight
of Institutions for Mental Diseases.
MACPAC.

7
https://www.macpac.gov/publication/reportto-congress-on-oversight-of-institutionsfor-mental-diseases/
H.R. 1319 / Public Law 117-2. American Rescue Plan
Act of 2021
Hollander, M. A. G., Jarlenski, M. P., Donohue, J. M.,
Cole, E. S., Kelley, D., & Krans, E. E. (2019). Medical specialty of buprenorphine prescribers for pregnant
women with opioid use disorder. American Journal
of Obstetrics & Gynecology, 220(5), 502-503. https:
//doi.org/10.1016/j.ajog.2019.01.226
Jumah, N. A. (2016). Rural, Pregnant, and Opioid Dependent: A Systematic Review. Substance Abuse:
Research and Treatment, 10s1, SART.S34547. https:
//doi.org/10.4137/SART.S34547
Indiana (2021). Letter to CMS from Indiana Medicaid
Director.
https://www.medicaid.gov/medicaid/
section-1115-demonstrations/downloads/
indiana-momii-withdrawal-ltr-06032021.pdf
KFF. (2017, November 10). Key Themes in Medicaid
Section 1115 Behavioral Health Waivers– Issue Brief.
KFF. https://www.kff.org/report-section/keythemes-in-medicaid-section-1115-behavioralhealth-waivers-issue-brief-9118/
KFF. (2018).
Medicaid Section 1915(c) Home
and
Community-Based
Services
Waivers
Participants, by Type of Waiver.
KFF.
https://www.kff.org/health-reform/stateindicator/participants-by-hcbs-waiver-type/
Maclean, J. C., Wen, H., Simon, K. I., & Saloner, B.
(2021). Institutions For Mental Diseases Medicaid
Waivers: Impact On Payments For Substance Use
Treatment Facilities. Health Affairs, 40(2), 326-333.
https://doi.org/10.1377/hlthaff.2020.00404
MACPAC. (2015). Behavioral Health in the Medicaid Program—People, Use, and Expenditures.
MACPAC. https://www.macpac.gov/publication/
behavioral-health-in-the-medicaid-program\
OT1\textemdashpeople-use-and-expenditures/
MACPAC. (2016). Integration of Behavioral and Physical Health Services in Medicaid. MACPAC. https:
//www.macpac.gov/publication/integration-ofbehavioral-and-physical-health-services-inmedicaid/
MACPAC. (2021). Legislative Milestones in Medicaid
and CHIP Coverage of Pregnant Women. MACPAC.
https://www.macpac.gov/legislativemilestones-in-medicaid-and-chip-coverageof-pregnant-women/
Maine Medicaid (2021).
Maine MOM. https:
//www.maine.gov/dhhs/oms/about-us/projectsinitiatives/mainemom
Missouri (2021).
Missouri Targeted Benefits for
Postpartum Women Section 1115 Waiver. https:
//www.medicaid.gov/medicaid/section-1115-

8
demo/demonstration-and-waiver-list/82361
MOMII (2021).
Maternal Opioid Misuse Indiana
Initative.
https://www.medicaid.gov/medicaid/
section-1115-demo/demonstration-and-waiverlist/103641
Patrick, S. W., Davis, M. M., Lehmann, C. U., Lehman,
C. U., & Cooper, W. O. (2015). Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. Journal of Perinatology: Official Journal of the California Perinatal Association, 35(8), 650-655. https:
//doi.org/10.1038/jp.2015.36
Public Law 97-35, Approved August 13, 1981 (95 Stat.
483). Omnibus Budget Reconciliation Act Of 1981.
Public Law 98-369, Approved July 18, 1984 (98 Stat.
494). Deficit Reduction Act Of 1984.
Public Law 111-148, as amended. Approved March 23,
2010). Patient Protection and Affordable Care Act.
Public Law 114-255, Approved December 13, 2016. 21st
Century Cures Act
Public Law 115-271, Approved October 24, 2018. (132
Stat. 3894). Substance Use-Disorder Prevention That
Promotes Opioid Recovery and Treatment for Patients
and Communities Act.
Ranji, U., Gomez, I., & 2021.
(2021, March
9).
Expanding Postpartum Medicaid Coverage.

Jason Semprini
KFF.
https://www.kff.org/womens-healthpolicy/issue-brief/expanding-postpartummedicaid-coverage/
Roosa Tikkanen et al. (2020) Maternal Mortality and
Maternity Care in the United States Compared to
10 Other Developed Countries Commonwealth Fund.
https://doi.org/10.26099/411v-9255
Roper, V., & Cox, K. J. (2017). Opioid Use Disorder in Pregnancy. Journal of Midwifery & Women’s
Health, 62(3), 329-340. https://doi.org/10.1111/
jmwh.12619
Semprini, J. (2020). Expanding the Capacity of Rural
Cancer Care With Teleoncology. Online Journal of
Rural Research & Policy, 15(2). https://doi.org/
10.4148/1936-0487.1101
USDA (2021):
Economics Research Services
Rural Urban Continuum Codes.
https:
//www.ers.usda.gov/data-products/ruralurban-continuum-codes.aspx
Weller, A. E., Crist, R. C., Reiner, B. C., Doyle, G. A.,
& Berrettini, W. H. (2021). Neonatal Opioid Withdrawal Syndrome (NOWS): A Transgenerational Echo
of the Opioid Crisis. Cold Spring Harbor Perspectives
in Medicine, 11(3), a039669. https://doi.org/10.
1101/cshperspect.a039669

Treating a Public Health Crisis for Rural Moms

9

APPENDIX
Table 1. State Inclusion Criteria

Decision

Reason

Colorado

Included

State has rural designated areas and published MOM
model documentation.

Model1

Indiana

Included

State has rural designated areas & CMS published
1115 Waiver documentation.

Waiver2

Missouri

Included

State has rural designated areas and CMS published
1115 Waiver documentation.

Waiver3

Maine

Included

State has rural designated areas and published MOM
model documentation.

Model4

Texas

Excluded

MOM Model documentation not publicly available6

Model5

Tennessee

Excluded

MOM Model documentation not publicly available6

Model5

West Virginia

Excluded

MOM Model documentation not publicly available6

Model5

Maryland

Excluded

No rural designated counties7

Model6

Sources:
1. https://hcpf.colorado.gov/maternal-opioid-misuse-model
2. https://www.medicaid.gov/medicaid/section-1115-demo/demonstration-and-waiver-list/103641
3. https://www.medicaid.gov/medicaid/section-1115-demo/demonstration-and-waiver-list/82361
4. https://www.maine.gov/dhhs/oms/about-us/projects-initiatives/mainemom
5. https://innovation.cms.gov/innovation-models/map#model=maternal-opioid-misuse-mom-model
6. https://www.ers.usda.gov/data-products/rural-urban-continuum-codes.aspx

Model/Waiver
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Table 2. Synthesizing State Approaches to Addressing Maternal Opioid Misuse through Medicaid

Colorado

Indiana

Missouri

MOM Model State Activity
Submitted 1115 Waiver
Implemented 1115 Waiver
Implemented CMMI Demonstration Model
MOM Model Demonstration Approaches
Insurance Payer Partner
Health System Provider Partner
Integrated Care
Expand Medicaid Coverage
Expand Medicaid Benefits
Include Telehealth in Medicaid MOM Model
Include Peer Support in Medicaid MOM Model
Include ECHO in Medicaid Mom Model
MOM Model Evaluation
Publicly Available Evaluation Protocol/Plan
Explicit Goal to Improve Rural Health
Note: Shaded cells indicate the state adopted the provision in their respective 1115 Waiver or Demonstration.

Maine
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Figure 1. Inclusion Flowchart

Notes:
1. CMS 202: Maternal Opioid Misuse (MOM) Innovation Model
https://innovation.cms.gov/innovation-models/map#model=maternal-opioid-misuse-mom-model
2. CMS 2021: Medicaid Waiver List
https://www.medicaid.gov/medicaid/section-1115-demo/demonstration-and-waiver-list/index.html
3. USDA ERS: Rural Urban Continuum Codes https://www.ers.usda.gov/data-products/rural-urban-continuum-codes.aspx
4. At the time of analysis (4/30/2021) IN, TX, TN, and WV did not make Medicaid Innovation MOM Model documentation publicly
available.

